| 1 | A bill to be entitled |
|----|---|
| 2 | An act relating to public records exemptions; |
| 3 | amending s. 1004.43, F.S.; clarifying the |
| 4 | public records exemption for proprietary |
| 5 | confidential business information owned or |
| 6 | controlled by the not-for-profit corporation |
| 7 | operating the H. Lee Moffitt Cancer Center and |
| 8 | Research Institute and its subsidiaries |
| 9 | relating to trade secrets; expanding the public |
| 10 | records exemption to include information |
| 11 | received from a person in this or another state |
| 12 | or nation or the Federal Government which is |
| 13 | otherwise exempt or confidential pursuant to |
| 14 | the laws of this or another state or nation or |
| 15 | pursuant to federal law; providing for future |
| 16 | review and repeal; providing a statement of |
| 17 | public necessity; amending s. 1004.445, F.S.; |
| 18 | creating a public records exemption for |
| 19 | proprietary confidential business information |
| 20 | owned or controlled by the Florida Alzheimer's |
| 21 | Center and Research Institute; specifying types |
| 22 | of information that are deemed proprietary |
| 23 | confidential business information; defining |
| 24 | "managed care" for purposes of the act; |
| 25 | creating a public meetings exemption for |
| 26 | specified meetings or portions of meetings of |
| 27 | the governing board of the Florida Alzheimer's |
| 28 | Center and Research Institute; providing for |
| 29 | future review and repeal; providing a statement |
| 30 | of public necessity; providing severability; |
| 31 | providing an effective date. |

1

First Engrossed

Be It Enacted by the Legislature of the State of Florida: 1 2 3 Section 1. Paragraph (b) of subsection (8) of section 1004.43, Florida Statutes, is amended to read: 4 1004.43 H. Lee Moffitt Cancer Center and Research 5 Institute.--There is established the H. Lee Moffitt Cancer б 7 Center and Research Institute at the University of South 8 Florida. (8) 9 (b) Proprietary confidential business information is 10 confidential and exempt from the provisions of s. 119.07(1) 11 and s. 24(a), Art. I of the State Constitution. However, the 12 Auditor General, the Office of Program Policy Analysis and 13 14 Government Accountability, and the State Board of Education, pursuant to their oversight and auditing functions, must be 15 given access to all proprietary confidential business 16 information upon request and without subpoena and must 17 18 maintain the confidentiality of information so received. As used in this paragraph, the term "proprietary confidential 19 business information" means information, regardless of its 20 form or characteristics, which is owned or controlled by the 21 not-for-profit corporation or its subsidiaries; is intended to 2.2 23 be and is treated by the not-for-profit corporation or its 24 subsidiaries as private and the disclosure of which would harm the business operations of the not-for-profit corporation or 25 its subsidiaries; has not been intentionally disclosed by the 26 corporation or its subsidiaries unless pursuant to law, an 27 28 order of a court or administrative body, a legislative 29 proceeding pursuant to s. 5, Art. III of the State Constitution, or a private agreement that provides that the 30 31

2

```
First Engrossed
```

information may be released to the public; and which is 1 2 information concerning: 3 1. Internal auditing controls and reports of internal 4 auditors; 5 2. Matters reasonably encompassed in privileged attorney-client communications; б 7 3. Contracts for managed-care arrangements, including 8 preferred provider organization contracts, health maintenance 9 organization contracts, and exclusive provider organization contracts, and any documents directly relating to the 10 negotiation, performance, and implementation of any such 11 contracts for managed-care arrangements; 12 13 4. Bids or other contractual data, banking records, 14 and credit agreements the disclosure of which would impair the efforts of the not-for-profit corporation or its subsidiaries 15 to contract for goods or services on favorable terms; 16 5. Information relating to private contractual data, 17 18 the disclosure of which would impair the competitive interest of the provider of the information; 19 6. Corporate officer and employee personnel 20 information; 21 22 7. Information relating to the proceedings and records 23 of credentialing panels and committees and of the governing 24 board of the not-for-profit corporation or its subsidiaries relating to credentialing; 25 8. Minutes of meetings of the governing board of the 26 not-for-profit corporation and its subsidiaries, except 27 28 minutes of meetings open to the public pursuant to subsection 29 (9); 30 31

3

| services that the corporation or its subsidiaries reasonably expect to be provided by competitors; 10. Trade secrets as defined in s. 688.002, including information relating to methods of manufacture or production, potential trade secrets, potentially patentable materials, or proprietary information received, generated, ascertained, or discovered during the course of research conducted by the not-for-profit corporation or its subsidiaries and business transactions resulting from such research, and reimbursement methodologies or rates; er 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or; 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 13 As used in this paragraph, the term "managed care" means 14 systems or techniques generally used by third-party payors or 15 their agents to affect access to and control payment for health care services. Managed-care techniques most often 16 include one or more of the following: prior, concurrent, and 17 appropriateness of services or site of services; contracts 18 with selected health care providers; financial incentives or 19 disincentives related to the use of specific providers, | 1 | 9. Information that reveals plans for marketing |
|--|----|---|
| 10. Trade secrets as defined in s. 688.002, including information relating to methods of manufacture or production, potential trade secrets, potentially patentable materials, or proprietary information received, generated, ascertained, or discovered during the course of research conducted by the not-for-profit corporation or its subsidiaries and business transactions resulting from such research, and reimbursement methodologies or rates; er 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report<u>; or</u>. 12. Any information received by the not-for-profit corporation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 23. As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 2 | services that the corporation or its subsidiaries reasonably |
| information relating to methods of manufacture or production, potential trade secrets, potentially patentable materials, or proprietary information received, generated, ascertained, or discovered during the course of research conducted by the not-for-profit corporation or its subsidiaries and business transactions resulting from such research, and reimbursement methodologies or rates; er 12 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report <u>; or</u> . 12 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 13 14 25 26 27 27 27 27 27 28 29 3 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or 25 their agents to affect access to and control payment for bealth care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and 28 29 3 appropriateness of services or site of services; contracts 30 30 31 32 32 33 34 35 35 35 36 36 37 37 37 37 37 37 37 37 37 37 37 37 37 | 3 | expect to be provided by competitors; |
| potential trade secrets, potentially patentable materials, or proprietary information received, generated, ascertained, or discovered during the course of research conducted by the not-for-profit corporation or its subsidiaries and business transactions resulting from such research, and reimbursement methodologies or rates; or 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or- 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or pursuant to the laws of this or another state or nation or pursuant to federal law. 22 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 4 | 10. Trade secrets as defined in s. 688.002, including |
| proprietary information received, generated, ascertained, or discovered during the course of research conducted by the not-for-profit corporation or its subsidiaries and business transactions resulting from such research, and reimbursement methodologies or rates; eff 12 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or- 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 22 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 5 | information relating to methods of manufacture or production, |
| discovered during the course of research conducted by the not-for-profit corporation or its subsidiaries and business transactions resulting from such research, and reimbursement methodologies or rates; or 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or; 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 6 | potential trade secrets, potentially patentable materials, or |
| 9 not-for-profit corporation or its subsidiaries and business transactions resulting from such research, and reimbursement methodologies or rates; or 12 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or; 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 22 23 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 7 | proprietary information received, generated, ascertained, or |
| transactions resulting from such research, and reimbursement methodologies or rates; or 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or; 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 22 23 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 8 | discovered during the course of research conducted by the |
| methodologies or rates; or 11 methodologies or rates; or 12 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or: 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 22 23 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 9 | not-for-profit corporation or its subsidiaries and business |
| 11. The identity of donors or prospective donors of property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or; 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 10 | transactions resulting from such research, and reimbursement |
| property who wish to remain anonymous or any information identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report <u>; or</u> . 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 23 23 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 11 | methodologies or rates; or |
| identifying such donors or prospective donors. The anonymity of these donors or prospective donors must be maintained in the auditor's report; or- <u>12. Any information received by the not-for-profit</u> <u>corporation or its subsidiaries from a person in this or</u> another state or nation or the Federal Government which is <u>otherwise exempt or confidential pursuant to the laws of this</u> or another state or nation or pursuant to federal law. As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 12 | 11. The identity of donors or prospective donors of |
| of these donors or prospective donors must be maintained in the auditor's report; or. 17 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 22 23 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 13 | property who wish to remain anonymous or any information |
| the auditor's report; or: 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 22 3 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 14 | identifying such donors or prospective donors. The anonymity |
| 17 12. Any information received by the not-for-profit corporation or its subsidiaries from a person in this or another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. 22 23 As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 15 | of these donors or prospective donors must be maintained in |
| 18 corporation or its subsidiaries from a person in this or 19 another state or nation or the Federal Government which is 20 otherwise exempt or confidential pursuant to the laws of this 21 or another state or nation or pursuant to federal law. 22 23 As used in this paragraph, the term "managed care" means 24 systems or techniques generally used by third-party payors or 25 their agents to affect access to and control payment for 26 health care services. Managed-care techniques most often 27 include one or more of the following: prior, concurrent, and 28 retrospective review of the medical necessity and 29 appropriateness of services or site of services; contracts 30 with selected health care providers; financial incentives or | 16 | the auditor's report <u>; or</u> . |
| another state or nation or the Federal Government which is otherwise exempt or confidential pursuant to the laws of this or another state or nation or pursuant to federal law. As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 17 | 12. Any information received by the not-for-profit |
| 20 otherwise exempt or confidential pursuant to the laws of this 21 or another state or nation or pursuant to federal law. 22 23 As used in this paragraph, the term "managed care" means 24 systems or techniques generally used by third-party payors or 25 their agents to affect access to and control payment for 26 health care services. Managed-care techniques most often 27 include one or more of the following: prior, concurrent, and 28 retrospective review of the medical necessity and 29 appropriateness of services or site of services; contracts 30 with selected health care providers; financial incentives or | 18 | corporation or its subsidiaries from a person in this or |
| or another state or nation or pursuant to federal law. As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 19 | another state or nation or the Federal Government which is |
| As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 20 | otherwise exempt or confidential pursuant to the laws of this |
| As used in this paragraph, the term "managed care" means systems or techniques generally used by third-party payors or their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 21 | or another state or nation or pursuant to federal law. |
| 24 systems or techniques generally used by third-party payors or 25 their agents to affect access to and control payment for 26 health care services. Managed-care techniques most often 27 include one or more of the following: prior, concurrent, and 28 retrospective review of the medical necessity and 29 appropriateness of services or site of services; contracts 30 with selected health care providers; financial incentives or | 22 | |
| their agents to affect access to and control payment for health care services. Managed-care techniques most often include one or more of the following: prior, concurrent, and retrospective review of the medical necessity and appropriateness of services or site of services; contracts with selected health care providers; financial incentives or | 23 | As used in this paragraph, the term "managed care" means |
| 26 health care services. Managed-care techniques most often 27 include one or more of the following: prior, concurrent, and 28 retrospective review of the medical necessity and 29 appropriateness of services or site of services; contracts 30 with selected health care providers; financial incentives or | 24 | systems or techniques generally used by third-party payors or |
| 27 include one or more of the following: prior, concurrent, and 28 retrospective review of the medical necessity and 29 appropriateness of services or site of services; contracts 30 with selected health care providers; financial incentives or | 25 | their agents to affect access to and control payment for |
| 28 retrospective review of the medical necessity and 29 appropriateness of services or site of services; contracts 30 with selected health care providers; financial incentives or | 26 | health care services. Managed-care techniques most often |
| <pre>29 appropriateness of services or site of services; contracts 30 with selected health care providers; financial incentives or</pre> | 27 | include one or more of the following: prior, concurrent, and |
| 30 with selected health care providers; financial incentives or | 28 | retrospective review of the medical necessity and |
| | 29 | appropriateness of services or site of services; contracts |
| 31 disincentives related to the use of specific providers, | 30 | with selected health care providers; financial incentives or |
| | 31 | disincentives related to the use of specific providers, |

4

| 1 | services, or service sites; controlled access to and |
|----|--|
| 2 | coordination of services by a case manager; and payor efforts |
| 3 | to identify treatment alternatives and modify benefit |
| 4 | restrictions for high-cost patient care. |
| 5 | Section 2. <u>Subparagraph 1004.43(8)(b)12., Florida</u> |
| 6 | Statutes, is subject to the Open Government Sunset Review Act |
| 7 | of 1995 in accordance with section 119.15, Florida Statutes, |
| 8 | and shall stand repealed on October 2, 2009, unless reviewed |
| 9 | and saved from repeal through reenactment by the Legislature. |
| 10 | Section 3. <u>(1) The Legislature finds that it is a</u> |
| 11 | public necessity that trade secrets of the H. Lee Moffitt |
| 12 | Cancer Center or its subsidiaries, as defined in section |
| 13 | 688.002, Florida Statutes, be confidential and exempt from |
| 14 | public disclosure. In accordance with that definition, a |
| 15 | "trade secret" consists of information that derives economic |
| 16 | value, actual or potential, from not being readily |
| 17 | ascertainable by others and that is the subject of reasonable |
| 18 | efforts to maintain its secrecy. The Legislature has |
| 19 | determined that the disclosure of such information would |
| 20 | adversely affect the H. Lee Moffitt Cancer Center and Research |
| 21 | Institute and its subsidiaries, which are resources of the |
| 22 | State of Florida, and would create an unfair competitive |
| 23 | advantage to a person receiving such information. |
| 24 | (2) Pursuant to section 119.15, Florida Statutes, the |
| 25 | Legislature finds that the amendment to subparagraph |
| 26 | 1004.43(8)(b)10., Florida Statutes, referencing information |
| 27 | relating to methods of manufacture or production, potential |
| 28 | trade secrets, potentially patentable materials, or |
| 29 | proprietary information received, generated, ascertained, or |
| 30 | discovered during the course of research conducted by the H. |
| 31 | Lee Moffit Cancer Center and Research Institute or any of its |
| | |

| 1 | subsidiaries, and business transactions resulting from such |
|----|--|
| 2 | research, does not substantially amend the existing exemption. |
| 3 | The Legislature finds and declares that each of the classes of |
| 4 | information specified meets the test of being a "trade secret" |
| 5 | within the meaning of term as defined in section 688.002, |
| 6 | Florida Statutes. To fulfill its legislative mandate of |
| 7 | research, education, treatment, prevention, and the early |
| 8 | detection of cancer, an exemption of confidential and |
| 9 | proprietary information relating to business transactions will |
| 10 | allow the not-for-profit corporation and its subsidiaries to |
| 11 | more effectively partner with other researchers. Although |
| 12 | information relating to business transactions may not qualify |
| 13 | as intellectual property, the terms and pricing of a research |
| 14 | transaction and, in some cases, the very fact of a research |
| 15 | transaction may be considered confidential information |
| 16 | concerning an entity. This exemption will assure collaborating |
| 17 | partners that their confidential business information will |
| 18 | remain confidential and exempt from public disclosure if |
| 19 | shared with the not-for-profit corporation or its |
| 20 | subsidiaries. The Legislature finds that the ability of the |
| 21 | not-for-profit corporation and its subsidiaries to conduct |
| 22 | meaningful scientific research and meet their obligations will |
| 23 | be significantly impaired if certain proprietary business |
| 24 | information or scientific research is not made confidential |
| 25 | and exempt from public disclosure. Specifically, the |
| 26 | Legislature finds that it is a public necessity to make exempt |
| 27 | and confidential proprietary business information or |
| 28 | scientific research that relates to methods of manufacture or |
| 29 | production, potential trade secrets, patentable material, |
| 30 | actual trade secrets as defined in section 688.002, Florida |
| 31 | Statutes, or proprietary information received, generated, |
| | |

| 1 | ascertained, or discovered by or through the not-for-profit |
|----|--|
| 2 | corporation or its subsidiaries because the disclosure of this |
| 3 | information would negate the benefit expected by exposing |
| 4 | valuable proprietary work to competitors. Business |
| 5 | transactions resulting from scientific research must be held |
| б | confidential and exempt from public records requirements |
| 7 | because the disclosure of such information would create an |
| 8 | unfair competitive advantage for the person receiving such |
| 9 | information. Such an advantage would adversely impact the |
| 10 | not-for-profit corporation and its subsidiaries. If |
| 11 | confidential and exempt information regarding research in |
| 12 | progress were released pursuant to a public records request, |
| 13 | others would be allowed to derive benefit from the research |
| 14 | without compensation or reimbursement to the not-for-profit |
| 15 | corporation or its subsidiaries. Without the exemptions |
| 16 | provided for in this act, the disclosure of confidential and |
| 17 | exempt information would place the not-for-profit corporation |
| 18 | or its subsidiaries on an unequal footing in the marketplace |
| 19 | as compared with other research competitors whose information |
| 20 | is kept confidential and exempt. The Legislature finds that |
| 21 | disclosure of confidential and exempt information would |
| 22 | adversely impact the not-for-profit corporation or its |
| 23 | subsidiaries in fulfilling the mission of research. |
| 24 | (3) The Legislature further finds that information |
| 25 | received by the not-for-profit corporation or its subsidiaries |
| 26 | from a person in this or another state or nation or the |
| 27 | Federal Government which is otherwise exempt or confidential |
| 28 | pursuant to the laws of this or another state or nation or |
| 29 | pursuant to federal law should remain exempt or confidential |
| 30 | because the highly confidential nature of cancer-related |
| 31 | research necessitates that the not-for-profit corporation or |
| | |

| 1 | its subsidiaries be authorized to maintain the status of |
|----|--|
| 2 | exempt or confidential information it receives from the |
| 3 | sponsors of research. Without the exemptions provided for in |
| 4 | this act, the disclosure of exempt and confidential |
| 5 | information would place the not-for-profit corporation on an |
| б | unequal footing in the marketplace as compared with its |
| 7 | private health care and medical research competitors that are |
| 8 | not required to disclose such exempt and confidential |
| 9 | information. The Legislature finds that the disclosure of such |
| 10 | exempt and confidential information would adversely impact the |
| 11 | not-for-profit corporation or its subsidiaries in fulfilling |
| 12 | their mission of cancer treatment, research, and education. |
| 13 | Section 4. Subsection (9) of section 1004.445, Florida |
| 14 | Statutes, is amended, and subsection (10) is added to said |
| 15 | section, to read: |
| 16 | 1004.445 Florida Alzheimer's Center and Research |
| 17 | Institute |
| 18 | (9) <u>(a)</u> The following information is confidential and |
| 19 | exempt from the provisions of s. $119.07(1)$ and s. 24, Art. I |
| 20 | of the State Constitution: |
| 21 | <u>1.(a)</u> Personal identifying information relating to |
| 22 | clients of programs created or funded through the Florida |
| 23 | Alzheimer's Center and Research Institute which is held by the |
| 24 | institute, <u>the</u> University of South Florida, or <u>the</u> State Board |
| 25 | of Education or by persons who provide services to clients of |
| 26 | programs created or funded through contracts with the Florida |
| 27 | Alzheimer's Center and Research Institute; |
| 28 | 2.(b) Any medical or health records relating to |
| 29 | patients which may be created or received by the institute; |
| 30 | 3. Proprietary confidential business information. As |
| 31 | used in this subparagraph, the term "proprietary confidential |
| | 0 |

| 1 | business information" means information, regardless of its |
|----|--|
| 2 | form or characteristics, which is owned or controlled by the |
| 3 | institute; is intended to be and is treated by the institute |
| 4 | as private and the disclosure of which would harm the business |
| 5 | operations of the institute; has not been intentionally |
| 6 | disclosed by the institute unless pursuant to law, an order of |
| 7 | a court or administrative body, a legislative proceeding |
| 8 | pursuant to s. 5, Art. III of the State Constitution, or a |
| 9 | private agreement that provides that the information may be |
| 10 | released to the public; and which is information concerning: |
| 11 | a. Trade secrets as defined in s. 688.002, including |
| 12 | information relating |
| 13 | (c) Materials that relate to methods of manufacture or |
| 14 | production, potential trade secrets, potentially patentable |
| 15 | material, actual trade secrets as defined in s. 688.002, or |
| 16 | proprietary information received, generated, ascertained, or |
| 17 | discovered during the course of research conducted by or |
| 18 | through the institute and business transactions resulting from |
| 19 | such research, and reimbursement methodologies or rates. $\dot{	au}$ |
| 20 | <u>b.(d)</u> The identity of a donor or prospective donor to |
| 21 | the Florida Alzheimer's Center and Research institute who |
| 22 | wishes to remain anonymous, and all information identifying |
| 23 | such donor or prospective donor <u>.</u> + |
| 24 | c.(e) Any information received by the institute in the |
| 25 | performance of its duties and responsibilities which is |
| 26 | otherwise confidential and exempt by law <u>.; and</u> |
| 27 | d.(f) Any information received by the institute from a |
| 28 | person from another state or nation or the Federal Government |
| 29 | which is otherwise confidential or exempt pursuant to that |
| 30 | state's or nation's laws or pursuant to federal law <u>.</u> |
| 31 | |
| | |

| 1 | e. Internal auditing controls and reports of internal |
|----|--|
| 2 | auditors. |
| 3 | f. Contracts for managed-care arrangements, including |
| 4 | preferred provider organization contracts, health maintenance |
| 5 | organization contracts, and exclusive provider organization |
| б | contracts, and any documents directly relating to the |
| 7 | negotiation, performance, and implementation of any such |
| 8 | contracts for managed-care arrangements. |
| 9 | g. Bids or other contractual data, banking records, |
| 10 | and credit agreements the disclosure of which would impair the |
| 11 | efforts of the institute to contract for goods or services on |
| 12 | favorable terms. |
| 13 | h. Information relating to private contractual data, |
| 14 | the disclosure of which would impair the competitive interest |
| 15 | of the provider of the information. |
| 16 | i. Corporate officer and employee personnel |
| 17 | information. |
| 18 | j. Information relating to the proceedings and records |
| 19 | of the credentialing panels and committees and of the |
| 20 | governing board of the institute relating to credentialing. |
| 21 | k. Minutes of exempt meetings of the governing board |
| 22 | of the institute. |
| 23 | 1. Information that reveals plans for marketing |
| 24 | services that the institute reasonably expects to be provided |
| 25 | by competitors. |
| 26 | |
| 27 | |
| 28 | As used in this subparagraph, the term "managed care" means |
| 29 | systems or techniques generally used by third-party payors or |
| 30 | their agents to affect access to and control payment for |
| 31 | health care services. Managed-care techniques most often |

| 1 | include one or more of the following: prior, concurrent, and |
|----|---|
| 2 | retrospective review of the medical necessity and |
| 3 | appropriateness of services or site of services; contracts |
| 4 | with selected health care providers; financial incentives or |
| 5 | disincentives related to the use of specific providers, |
| б | services, or service sites; controlled access to and |
| 7 | coordination of services by a case manager; and payor efforts |
| 8 | to identify treatment alternatives and modify benefit |
| 9 | restrictions for high-cost patient care. |
| 10 | (b) The Auditor General, the Office of Program Policy |
| 11 | Analysis and Government Accountability, and the State Board of |
| 12 | Education, pursuant to their oversight and auditing functions, |
| 13 | shall be given access to all proprietary confidential business |
| 14 | information upon request and without subpoena and must |
| 15 | maintain the confidentiality of information so received. |
| 16 | (c) Any governmental entity that demonstrates a need |
| 17 | to access such confidential and exempt information in order to |
| 18 | perform its duties and responsibilities shall have access to |
| 19 | such information and shall otherwise keep such information |
| 20 | confidential and exempt. |
| 21 | (d) This <u>subsection</u> section is subject to the Open |
| 22 | Government Sunset Review Act of 1995 in accordance with s. |
| 23 | 119.15 and shall stand repealed on October 2, <u>2009</u> 2006 , |
| 24 | unless reviewed and saved from repeal through reenactment by |
| 25 | the Legislature. |
| 26 | (10)(a) Meetings or portions of meetings of the |
| 27 | governing board of the Florida Alzheimer's Center and Research |
| 28 | Institute at which information is discussed that is made |
| 29 | confidential and exempt pursuant to subsection (9) are exempt |
| 30 | from s. 286.011 and s. 24(b), Art. I of the State |
| 31 | Constitution. |

| - 1 | (h) mhin mhin shi a bhin bhi bh bh cum Garannach |
|-----|--|
| 1 | (b) This subsection is subject to the Open Government |
| 2 | Sunset Review Act of 1995 in accordance with s. 119.15 and |
| 3 | shall stand repealed on October 2, 2009, unless reviewed and |
| 4 | saved from repeal through reenactment by the Legislature. |
| 5 | Section 5. <u>The Legislature finds that it is a public</u> |
| б | necessity that proprietary confidential business information |
| 7 | owned or controlled by the Florida Alzheimer's Center and |
| 8 | Research Institute, which includes reimbursement methodologies |
| 9 | or rates; internal auditing controls and reports of internal |
| 10 | auditors; contracts for managed-care arrangements and any |
| 11 | documents directly relating to the negotiation, performance, |
| 12 | and implementation of any such contracts for managed-care |
| 13 | arrangements; bids or other contractual data, banking records, |
| 14 | and credit agreements; information relating to private |
| 15 | contractual data; corporate officer and employee personnel |
| 16 | information; information relating to the proceedings and |
| 17 | records of the credentialing panels and committees and of the |
| 18 | governing board of the institute relating to credentialing; |
| 19 | minutes of meetings of the governing board of the institute; |
| 20 | and information that reveals plans for marketing services that |
| 21 | the institute reasonably expects to be provided by competitors |
| 22 | be held confidential and exempt from public disclosure. The |
| 23 | institute must compete directly with its private-sector |
| 24 | counterparts. Its economic survival depends on the institute s |
| 25 | ability to so compete. As such, these exemptions are necessary |
| 26 | because release of this information would adversely impact the |
| 27 | institute in the competitive health care and medical research |
| 28 | environment. Disclosure of such information would place the |
| 29 | institute on an unequal footing in the marketplace as compared |
| 30 | with private health care providers that are not required to |
| 31 | disclose such confidential and exempt information. The highly |
| | |

| 1 | confidential nature of Alzheimer-related research discoveries |
|----|--|
| 2 | necessitates that the institute be authorized to maintain |
| 3 | confidential information it receives from, or generates for, |
| 4 | the sponsors of its research. Accordingly, disclosure of such |
| 5 | information would impede the effective and efficient |
| 6 | administration of the Florida Alzheimer's Center and Research |
| 7 | Institute and would create an unfair competitive advantage for |
| 8 | persons or entities receiving such information. Also, such |
| 9 | information is of a sensitive, personal nature regarding |
| 10 | corporate officers and employees. Disclosure of such |
| 11 | information could be harmful to the officer or employee. It is |
| 12 | likewise a public necessity that certain meetings or portions |
| 13 | of meetings of the governing board of the institute be closed |
| 14 | in order to protect the competitive interest of the institute |
| 15 | and to quarantee the ability of the governing board to fulfill |
| 16 | its Alzheimer's disease research and teaching mission for the |
| 17 | benefit of the public. Furthermore, disclosing information |
| 18 | made confidential and exempt pursuant to the institute s |
| 19 | public records exemption via an open meeting defeats the |
| 20 | purpose of the public records exemption. |
| 21 | Section 6. <u>If any provision of this act or its</u> |
| 22 | application to any person or circumstance is held invalid, the |
| 23 | invalidity does not affect other provisions or applications of |
| 24 | the act which can be given effect without the invalid |
| 25 | provision or application, and to this end the provisions of |
| 26 | this act are declared severable. |
| 27 | Section 7. This act shall take effect upon becoming a |
| 28 | law. |
| 29 | |
| 30 | |
| 31 | |